Company Overview of California Stem Cell, Inc.
California Stem Cell, Inc. discovers, produces, and supplies human cell populations for research, diagnostic, clinical, and therapeutic applications. The company offers stem cell media, such as serum-free media for propagation of human embryonic stem cell (hESC); serum-free media for propagation of human myoblasts; serum-free media formulation to propagate hESC and bias their differentiation to ectodermal lineages; and products for laboratory research purposes. The company also provides human motor neuron progenitors, human cardiac progentior cells, and human neuronal progentior cells for screening and predictive toxicology applications, which are derived from human embryonic stem cells. In ...
5251 California Avenue
Irvine, CA 92617
Founded in 2005
Key Executives for California Stem Cell, Inc.
Chairman of The Scientific Advisory Board, Chief Executive Officer and President
Chief Development Officer
Compensation as of Fiscal Year 2015.
California Stem Cell, Inc. Key Developments
Neostem, Inc., California Stem Cell, Inc. - M&A Call
Apr 11 14
To discuss the definitive agreement to acquire California Stem Cell, Inc
U.S. Food and Drug Administration Approves California Stem Cell, Inc.'s Phase II Cancer Stem Cell Clinical Trial for Ovarian Cancer
Feb 18 14
California Stem Cell, Inc. announced that the U.S. Food and Drug Administration has approved the company's application to begin a Phase II clinical trial exploring the potential of a patient specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer. The randomized, double blind study is the company's second cancer therapy approved for clinical trials by the FDA, bolstering its platform approach to treating late stage solid-tumor cancers. The company's patient specific approach to treating metastatic melanoma, recently approved to begin a Phase III trial, provided sufficient safety data to proceed directly to a Phase II study in ovarian cancer. The study design randomizes an estimated 99 adult female patients to two treatment arms. The treatment group will receive Ovapuldencel-T, which is a combination of autologous dendritic cells loaded with irradiated autologous tumor cells in GM-CSF. Ovapuldencel-T is created by first isolating cancer stem cells from the patient's resected tumor sample, then enriching, inactivating and combining these cells with dendritic cells or antigen presenting immune cells which are harvested from the patient's blood. The control group will receive the ‘MC’ treatment, harvested from the patient's blood combined with GM-CSF, granulocyte macrophage colony stimulating factor, a white blood cell growth factor. The trial design calls for both groups to receive subcutaneous injections of their respective treatment weekly for three consecutive weeks, then monthly for the following five months. The trial is expected to last approximately sixty months, including enrollment, treatment, and long term patient follow-up.
California Stem Cell, Inc. Presents at 9th Annual New York Stem Cell Summit, Feb-18-2014 11:00 AM
Jan 25 14
California Stem Cell, Inc. Presents at 9th Annual New York Stem Cell Summit, Feb-18-2014 11:00 AM. Venue: The Convene, Downtown, 32 Old Slip (between Water St. and FDR), New York, NY 10005, United States. Speakers: Hans S. Keirstead, Chairman of the Scientific Advisory Board.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|